Case Report

Bilateral Synchronous Testicular Plasmacytoma as Extramedullary Relapse in High-Risk Multiple Myeloma Patient

Gonzalez de la Calle V1, Alonso S1, Del Carmen S2, Dávila J1, Antúnez P2, Gomez Veiga P1, Lopez-Godino O1, Puig N1, Gutiérrez N1, Lopez-Corral L1, Ocío EM1, Caballero MD1 and Mateos MV* 1

1Hematology Department, University Hospital of Salamanca-IBSAL, Spain
2Pathology Department, University Hospital of Salamanca-IBSAL, Spain
3Urology Department, University Hospital of Salamanca-IBSAL, Spain

*Corresponding author: Mateos MV, Hematology Department, University Hospital of Salamanca, Paseo de San Vicente 88-182, 37007, Spain. Fax: 34 923 29 11 00; Email: mvmateos@usal.es

Received: December 19, 2014; Accepted: March 16, 2015; Published: March 18, 2015

Case Presentation

A 43 year-old man with no significant medical history, in September 2011, anaemia (Hb: 8.8 g/dl) and hyperproteinemia (13.6 g/dL), were detected both in a medical check-up. The patient was asymptomatic and physical examination was unremarkable, 1.75 m tall, with a BMI of 23 kg/m2. Serum protein electrophoresis and immunofixation assay demonstrated the presence of Ig G-κ monoclonal protein (7.87 g/dL). The required work-up confirmed the diagnosis of Multiple Myeloma (MM) Ig G-Kappa, ISS-2. Anaemia was the only end-organ damage sign. Bone marrow aspiration showed 70% infiltration by Plasma Cells (PC), all of them aberrant. FISH analysis showed t (4;14) and del gen RB (13q14).

Induction therapy with chemotherapy VBCMP (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone) was initiated, but in the absence of response, VTD [1] (bortezomib-thalidomide-dexamethasone) was achieved followed by tandem Autologous Stem Cell Transplantation (ASCT) with Mel 200 and BuMel as conditioning regimens due to the presence of high-risk features. The M-protein remained persistent (0.24 g/dL) on day 100 after second ASCT. The patient received 4 VRD consolidation cycles (bortezomib-lenalidomide-dexamethasone) achieving Immunophenotypic complete response, followed by prednisone/interferon as maintenance.

Eleven months from second ASCT, biochemical relapse was detected. Considering that we were dealing a young MM patient early relapsing after ASCT and with high risk features, together with the availability of an HLA-identical sibling donor, we planned to give one cycle of VRD to maintain the disease under control and to immediately proceed to allogeneic Stem Cell Transplantation (allo-SCT) with reduced-intensity conditioning. Although the patient remained asymptomatic with negative examination findings, a symmetrical 18F-Fluoro-2-Deoxyglucose (FDG) uptake in the testes was identified on the PET/CT (Figure 1) performed as part of the standard work-up prior allo-SCT. Several hypoechoic nodules with hypervascularity were identified by ultrasound scan (Figure 2) and fine-needle aspiration showed infiltration by plasma cells. Immunohistochemical analysis revealed positivity for CD138 with restriction for Kappa light chain, and flow cytometry analysis confirmed also the presence of aberrant plasma cells (90%). Serum M-protein was 0.15 g/dL, with no evidence of plasma cells in peripheral blood or spinal fluid. Bone marrow aspirate showed only 2% of plasma cells, most of them (85%) aberrant by flow cytometry and identical to those identified in the testicular biopsy (Figure 3). Therefore, an asymptomatic bilateral and synchronous testicular extramedullary relapse was diagnosed.

In the absence of therapeutic guidelines, we proposed bilateral orchiectomy and local radiotherapy (200cGy, 15 sessions), plus systemic chemotherapy (D-PACE: dexamethasone, cisplatin,
doxorubicin, cyclophosphamide and etoposide). Pathology confirmed bilateral synchronous testicular plasmacytoma (Figure 4 and 5). The patient subsequently received allo-peripheral blood SCT using myeloablative conditioning (total body irradiation plus cyclophosphamide). No significant transplant-related complications emerged, with the exception of intestinal acute Graft-Versus-Host Disease (GVHD) (grade Ia) treated with topical steroids. On day +100 after allo-SCT, serum M-protein (0.1 g/dL) and 1% of BM CP (77% aPC) are still present, although complete chimerism is achieved and PET/CT remains negative. Our goal is to maintain the lowest immunosuppression levels as possible to achieve graft-versus-tumour effect.

Discussion

MM is a neoplastic plasma cell disorder characterized by the proliferation of clonal plasma cells in the bone marrow with monoclonal immunoglobulin production [2]. When clonal PC arises in tissues other than bone are called Extramedullary Plasmacytomas (EMP). EMP constitute 3-5% of all plasma cell neoplasms [3]. The incidence of EMP is up to 18% at MM diagnosis and higher at relapse [4]. The commonest involved sites are the upper respiratory and the gastrointestinal tracts, whereas testicular involvement is very rare [5] (0.03-0.1% of all primary and secondary testicular tumors) [6]. Differential diagnosis with spermatocytic seminoma and testicular lymphoma [7] has to be made. In our patient, normal serum tumor markers discarded this diagnosis and the testicular fine-needle aspiration was performed.

Less than 80 cases of testicular plasmacytomas are published, even more exceptionally is the bilateral and synchronous involvement. To our knowledge, 3 cases [8-10] of bilateral and synchronous testicular plasmacytomas have been published. Painless scrotal swelling is usually present, but in our patient the testicular involvement was completely asymptomatic. PET/CT is included in our work-up before allo-SCT and we detected the testicular involvement. Otherwise, it may be that we have misunderstood a relapse after allo-SCT. No prospective studies have ever been conducted to evaluate the efficacy of therapy, and there is not any standard treatment. Orchiectomy alone or in combination with radiotherapy and chemotherapy have been used, even SCT [11] in selected cases. Although the impact of the disease is unknown, however extramedullary disease has been associated with a poor prognosis [12,13].

The role of Positron Emission Tomography-Computed Tomography (PET/TC) [14] is very relevant in the diagnosis of plasmacytomas, particularly in this patient, because this technique...
allowed detecting an asymptomatic testicular relapse. PET/CT has also a role in the assessment of response, because it is able to distinguish between active and inactive disease, and several studies are evaluating this role.

Although allogeneic SCT is a potentially curative option in MM, the introduction of new drugs together with the transplant-related mortality/morbidity and the high relapse risk make its use controversial [15]. It should be reconsidered with new agents, reduced intensity conditioning and selected patients (those with early relapse after optimal induction and ASCT and poor prognostic features like our patient) in the context of clinical trials. In our local experience [16], the transplant related mortality was of only 14%, with 41% of the patients alive at 5 years after allo-SCT.

Conclusion

We report a young multiple myeloma patient, with a high risk disease and a testicular extramedullary relapse after tandem ASCT. In this case, implementation of PET/CT pre-alloSCT allowed detecting an early and asymptomatic extramedullary relapse. The singularity of this case is that synchronous and bilateral testicular involvement in MM is extremely rare. Treatment strategy should combine surgery, local radiotherapy, chemotherapy and, in selected patients, allo-SCT. Even though, we need more prospective studies to evaluate the role of PET/CT in MM, this patient shows that MM is not only a disease within bone marrow and extramedullary assessment is useful in selected patients, and it will be part of standard management in the near future.

References